Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENNY PCI pilot pharmacodynamic study of prolonged enoxaparin in primary PCI
2017-000485-29Phase 4Completed
- Sponsor
- Dr
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enoxaparin in myocardial infarction (MI), sponsored by Dr. Primary endpoint: Anti-factor Xa activity level. Started Mar 2017; status: completed.
02
Drugs
enoxaparin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2017-000485-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000485-29.